Who Paid My Doc
Peter Polverini
Dentist, Oral and Maxillofacial Pathology Ann Arbor, MI Doctor of Dentistry
NPI 1699808857 CMS profile 696693
1011 N University Ave, Ann Arbor, MI 48109
General payments
$3,126
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Peter Polverini of Ann Arbor, MI is reported in the CMS Open Payments database as having received $3,126 across 26 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 85th percentile of Dentist, Oral and Maxillofacial Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $891 | 6 | |
| 2021 | General | $2,235 | 20 |
Beside peers
- Peter Polverini
- Dentist, Oral and Maxillofacial Pathology median
- Middle half of Dentist, Oral and Maxillofacial Pathology
- National median
In program year 2025, general payments to Peter Polverini were reported at $0. Among 128 Dentist, Oral and Maxillofacial Pathology profiles paid that year, the median was $91 and the middle half received between $35 and $330.
Show as a table
| Year | Peter Polverini | Dentist, Oral and Maxillofacial Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $106 | $28–$326 | $163 |
| 2020 | $0 | $109 | $33–$500 | $114 |
| 2021 | $2,235 | $104 | $30–$557 | $132 |
| 2022 | $891 | $104 | $37–$432 | $149 |
| 2023 | $0 | $152 | $41–$372 | $160 |
| 2024 | $0 | $100 | $38–$354 | $164 |
| 2025 | $0 | $91 | $35–$330 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 3 billing codesPaid by Medicare
$2,353
Medicare patients
37
Services billed
40
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 49% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
26 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Dentist, Oral and Maxillofacial Pathology in Michigan
Dalbert Fear Jr
Dentist, Oral and Maxillofacial Pathology · Ann Arbor, MI
Fredric Bonine
Dentist, Oral and Maxillofacial Pathology · Brighton, MI
Nicole Wax
Dentist, Oral and Maxillofacial Pathology · Linden, MI
Albert Wesley
Dentist, Oral and Maxillofacial Pathology · Oakland, MI
Brent Martin
Dentist, Oral and Maxillofacial Pathology · Ann Arbor, MI
Gary Dwight
Dentist, Oral and Maxillofacial Pathology · East Lansing, MI
Related records
Dentist, Oral and Maxillofacial Pathology in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Dentist, Oral and Maxillofacial Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.